FDAsafety guidance66% confidence
Human Drug Compounding
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as AbbVie; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.
Supporting Context
- Therapeutic area
- Dermatology · Autoimmune Disease
- Sub-indication
- Immunology
Related signal: FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus